$DCBO

Docebo Inc (DCBO) Shares Fall 8.5% -- What GF Score of 70 Tells Investors

Docebo Inc (DCBO) shares dropped 8.5% to $14.70, marking a significant 33.8% year-to-date decline and nearly 50% over the past year. Despite its GF Score™ of 70/100, indicating an "Above Average" potential for long-term returns, the stock is considered significantly undervalued with a GF Value™ of $59.61. Investors are advised to consider the company's strong financial health and growth prospects against its current weak profitability and momentum.

Original reporting
GuruFocus · GuruFocus News
Published Apr 11, 2026, 12:10 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 11, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Docebo Inc (DCBO) Shares Fall 8.5% -- What GF Score of 70 Tells Investors — source image
Decision brief

The 30-second read

$DCBOBearishMed
01

Why it matters

The undervaluation suggests a possible re-rating in the future, but current weak profitability and momentum could prolong volatility.

02

Market read

The company's valuation and recent stock performance are relevant for long-term investors and those monitoring growth tech valuations.

03

What to watch

Potential upcoming earnings reports or sector shifts that could influence stock performance; macroeconomic factors affecting growth tech valuations.

Timing: moderate; the recent decline indicates a possible entry point for swing or long-term investors.

Background

Docebo Inc has experienced a significant stock decline year-to-date, despite a solid GF Score indicating potential for long-term returns.

Company-level read

Ticker impact

$DCBOBearishMedium confidence
Context

Primary focus of the news, significant stock decline and valuation discussion.

Expected impact

Potential rebound over the medium to long term due to undervaluation, but near-term volatility may persist.

Evidence & confidence

The significant drop and undervaluation suggest a buying opportunity, but weak profitability and momentum introduce uncertainty.

Market effects

The decline may reflect sector-wide concerns about growth prospects or valuation adjustments.

Limited; the news pertains primarily to a U.S.-listed company, with minimal regional impact.

Low; the company's valuation and performance are more relevant to specific investors than to global markets.

Counterpoint

The decline may be an overreaction, presenting a buying opportunity given the company's undervaluation and growth prospects.

Key entities

  • Docebo Inc

    A provider of cloud-based learning management systems.

Related articles

$DCBOMedAI 8/10

Docebo Inc. Announces Substantial Issuer Bid, Preliminary Unaudited Second Quarter 2026 Financial Results, Initial Q3-2026 and Revised FY2026 Guidance

Docebo Inc. (NASDAQ: DCBO, TSX: DCBO) said its board approved a substantial issuer bid to repurchase up to US$70m of common shares at US$20.40 each, funded by about US$10m cash and a US$60m credit-facility draw. Preliminary Q2 2026 results: subscription revenue US$63.5-63.7m, total revenue US$68.3-68.5m, adjusted EBITDA US$10.9-11.1m. Full results due Aug 7, 2026.

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).